ACR exact-submission catalog context
ACR AI Central provides an exact-submission model card for OnQ Neuro; FDA labeling remains controlling for clinical use, limitations, and performance.
exact submission ยท checked 2026-09-09FDA-cleared profile
OnQ Neuro
CorTechs Labs, Inc
Authorized purpose: Analyzes neurological MR images for automated segmentation, volumetric quantification, reporting, fusion, and longitudinal comparison of known pathologically confirmed brain tumors.
Evidence status: each field states its source quality, applicability, and review date. Research pending, information not established, and vendor documentation pending remain distinct outcomes.
Product overview
Start with the essentials
Authorized purpose: Analyzes neurological MR images for automated segmentation, volumetric quantification, reporting, fusion, and longitudinal comparison of known pathologically confirmed brain tumors.
Overview status: Source-reviewed overview
- What does this software do? Authorized purpose: Analyzes neurological MR images for automated segmentation, volumetric quantification, reporting, fusion, and longitudinal comparison of known pathologically confirmed brain tumors.
- Which images or clinical context are in scope? Modality: MRI Anatomy or clinical context: Brain; pathologically confirmed brain tumors Input: DICOM neurological MR images, including DWI, from MRI or PACS workflows for adult patients with confirmed brain tumors.
- Who uses it? Intended users: Radiologists, oncologists, and other trained clinicians or personnel.
- What does the software produce? Output: Numerical volumes, grayscale maps, graphical color overlays, DICOM image series and reports, automated segmentation, quantification, fusion, and longitudinal comparisons.
- What is its most important limitation? Key limitation: Adults with known or confirmed pathologically diagnosed brain cancer; output is complementary information and the physician retains final diagnosis and treatment responsibility.
Clinical takeaway
Clinical role: Analyzes neurological MR images for automated segmentation, volumetric quantification, reporting, fusion, and longitudinal comparison of known pathologically confirmed brain tumors.
Evidence takeaway
Evidence from the reviewed source record: FDA-reported software verification and validation, independent-test-set segmentation comparison against expert labels, and separate DWI unit, system, and clinical validation; no numeric claim is promoted.
Clinical details
What this tool is for
Start with the authorized purpose, then verify how it fits your service line and reading workflow.
- Exact purpose
- Analyzes neurological MR images for automated segmentation, volumetric quantification, reporting, fusion, and longitudinal comparison of known pathologically confirmed brain tumors.
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
- Intended users
- Radiologists, oncologists, and other trained clinicians or personnel.
FDA packet user statement.
- Care setting and population
- Adult
Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.
- Workflow role
- Segmentation or contouring
Conservative normalization of explicit wording in an exact-submission source.
- Required input
- DICOM neurological MR images, including DWI, from MRI or PACS workflows for adult patients with confirmed brain tumors.
FDA packet input and population scope.
- Output and human action
- Numerical volumes, grayscale maps, graphical color overlays, DICOM image series and reports, automated segmentation, quantification, fusion, and longitudinal comparisons.
FDA packet output scope.
- Limitations
- Adults with known or confirmed pathologically diagnosed brain cancer; output is complementary information and the physician retains final diagnosis and treatment responsibility.
Exact FDA limitation boundary.
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Implementation
Questions for IT, informatics, and operations
Use these fields to structure a vendor demo, security review, and implementation estimate.
- Integration
- Standards-based DICOM/PACS integration was identified in the FDA submission materials; compatibility with a specific PACS, RIS, EHR, or orchestrator requires confirmation.
Normalized from the prior exact-submission review. Confirm interface versions and local compatibility during technical evaluation.
- Deployment and data flow
- Hybrid
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
- Security and privacy
- Vendor documentation pending
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Training and support
- Vendor documentation pending
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Monitoring and change control
- Vendor documentation pending
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Evidence
Performance evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
- Evidence summary
- FDA-reported software verification and validation, independent-test-set segmentation comparison against expert labels, and separate DWI unit, system, and clinical validation; no numeric claim is promoted.
Submission evidence only.
- Reported sensitivity
- Research pending
This field has not been curated yet.
- Reported specificity
- Research pending
This field has not been curated yet.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
OnQ Neuro regulatory performance study summary
- DesignStand-Alone Performance
- PopulationAdult
- Scopeexact submission
- Tested version1.2
- IndependenceIndependence not established
K210831
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Costs and setup
Budget and ongoing governance
These are common procurement questions; unknown values remain visible until a source supports them.
- Pricing and total cost
- Vendor documentation pending
No public price or quote for the exact K210831 configuration was established in this review.
- Reimbursement and coding
- Not established in reviewed sources
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
- Postmarket safety review
- The exact-identifier FDA recall query returned no native recall record for K210831. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
Buyer worksheet
Open questions to take to the vendor
- Verify security and privacy controls: Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
- Verify training: Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
- Verify pricing and total cost: No public price or quote for the exact K210831 configuration was established in this review.
- Verify reimbursement and coding relevance: No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
- Verify local validation and lifecycle monitoring: Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Research record
What has been checked
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Sources & history
How this profile was documented
Open the ledger for source dates, scope, and research-record updates.
View source ledger and history
Source ledger
-
FDA K210831: OnQ Neuro
Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary
-
Artificial Intelligence-Enabled Medical Devices
Scope: regulatoryIdentity, modalityContext
-
OnQ Neuro model card (K210831)
Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, anatomy, evidenceStudies
-
PubMed biomedical literature index
Scope: evidenceDiscovery
-
ClinicalTrials.gov study registry
Scope: evidenceDiscovery, studyStatus
-
openFDA Device Recall API
Scope: recallDiscovery, nativeSubmissionMatching
-
openFDA exact recall query for K210831
Scope: postmarketSafety
Research history
-
K210831 FDA decision
Regulatory record
510(k)
-
Source-review record updated
Research record
fda record reviewed
-
Reader overview source-reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Related tools to compare
FDA-cleared K253413
LiverMultiScan (v6.0)
Perspectum, Ltd.
LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC...
- Modality
- MRI
- Anatomy
- Liver
- Decision
- 2026-03-09
FDA-cleared K252922
Neosoma Brain Mets
Neosoma, Inc.
Neosoma Brain Mets semi-automatically segments and contours previously diagnosed brain metastases on T1 post-contrast brain MRI to support radiation-oncology treatment planning.
- Modality
- MRI
- Anatomy
- Brain; previously diagnosed brain metastases
- Decision
- 2025-12-17
FDA-cleared K251766
TumorSight Viz
SimBioSys, Inc.
TumorSight Viz processes dynamic contrast-enhanced breast MRI for patients with biopsy-proven early-stage or locally advanced breast cancer, providing registration, subtraction,...
- Modality
- MRI
- Anatomy
- Breast
- Decision
- 2025-07-08
FDA-cleared K242825
Prenuvo Body Composition
Prenuvo
Prenuvo Body Composition is software that non-invasively quantifies fat, muscle, and organs from compatible MR DICOM datasets and displays internal body information, including...
- Modality
- MRI
- Anatomy
- Whole-body anatomy, liver, organs, fat, and muscle
- Decision
- 2025-01-17